查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1471211

原電池市場：按原產地、電池類型和最終用戶分類 - 2024-2030 年全球預測

Primary Cells Market by Origin (Animal Primary Cells, Human Primary Cells), Cell Type (Dermatocytes, Gastrointestinal Cells, Heart Cells), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年原電池市場規模為14.3億美元，預計2024年將達16億美元，2030年將達31.8億美元，複合年成長率為12.10%。

原代細胞是組織和器官的基本組成部分，表現出與其起源相似的自然生物學行為，使其成為各種科學應用中的重要工具。對再生醫學和細胞研究的投資不斷增加，推動了開發原代細胞創新治療解決方案的需求。 CRISPR基因編輯技術等技術進步為標靶治療提供了更精確的操作工具，從而擴大了原代細胞的用途。然而，由於影響其生物學的遺傳和環境因素，原代細胞可能表現出供體之間的變異性，這可能會限制研究環境中的重現性。然而，學術機構、實驗室和生物製藥製造商之間日益加強的生命科學合作預計將有助於尋找主要的細胞治療方法。

主要市場統計
基準年[2023] 14.3億美元
預測年份 [2024] 16億美元
預測年份 [2030] 31.8億美元
複合年成長率（%） 12.10%

起源：越來越偏好原代人類細胞以準確地代表人類細胞反應

原代動物細胞直接從動物組織中分離出來，保留了許多原始的生理特性，使其成為體外和臨床前研究的寶貴工具。研究人員通常使用原代動物細胞來研究生物過程、篩檢藥物和開發新的疾病治療方法。使用動物原代細胞的優點包括易於取得、與人類原代細胞相比成本低廉以及能夠模擬物種特異性的治療反應。人類原代細胞直接源自人體組織，並保留了許多與其來源組織相似的特徵。對於理解人類生物學、藥物發現、病理學、毒性測試和再生醫學應用至關重要。與永生化細胞株或動物模型相比，原代人類細胞培養物可以更準確地代表人類細胞反應。對於需要更高生物學相關性的應用，尤其是研究人類特異性疾病和開發患者治療方法，原代人類細胞通常是首選。

細胞類型：在藥物開發和毒性測試中增加皮膚細胞的使用

皮膚細胞對於皮膚生物學、創傷治療和皮膚疾病的研究人員至關重要。它也廣泛應用於藥物開發和毒性測試。胃腸細胞包括胃腸道中存在的各種類型的細胞，對於腸道健康、營養吸收和胃腸道疾病的研究至關重要。心肌細胞或心肌細胞是涉及心臟發育、功能和疾病建模的心血管研究的核心。造血幹細胞（造血幹細胞）可產生所有類型的血細胞，在再生醫學以及白血病和淋巴瘤等血液疾病的移植治療中具有多種應用。原代肝細胞對於涉及肝功能、代謝和藥物毒性測試的研究至關重要。肺部研究在很大程度上依賴原代肺細胞來研究氣喘、慢性阻塞性肺病和肺癌等呼吸道疾病。肌肉骨骼細胞由形成骨骼、軟骨和肌肉的細胞組成，對於肌肉骨骼疾病、再生醫學應用和組織工程解決方案的研究至關重要。我們描述了一個富有洞察力的腎病學研究模型，包括腎臟或腎原代細胞腎病變進展和腎功能藥物毒性評估。

最終用戶：擴大原代細胞在生命科學公司中的使用可確保實驗過程中獲得準確的結果。

生技、製藥和醫療設備等生命科學公司在研發活動上投入大量資金。這些公司需要原代細胞來進行藥物發現、毒性測試、細胞療法開發、再生醫學應用和生物產品製造。這些公司需要具有良好表現型的高品質原代細胞，以便在實驗過程中獲得準確的結果。研究機構包括專注於闡明基本生物過程和疾病機制的學術機構和政府資助的實驗室。原代細胞對於研究工作至關重要，因為它們作為模型系統來研究各種實驗條件下的細胞過程和反應。研究機構喜歡符合倫理且有適當文件記錄的多樣化原代細胞，以確保不同實驗室之間的可重複性。

區域洞察

美洲地區顯示出顯著的成長，主要是由於美國和加拿大等國家成熟的生物技術和製藥行業的存在。細胞培養方法中先進技術的快速採用以及研發活動投資的增加對該地區的強勁表現做出了貢獻。此外，旨在推廣使用原代細胞的新型治療方法的政府舉措正在推動這一領域的成長。在亞太地區，中國和印度等國家的生物製藥領域正在經歷顯著擴張。這是由於老年人口不斷增加，慢性病盛行率很高，需要創新的治療方法、醫療成本不斷上升以及對研發活動的關注增加。因此，該地區對原電池的需求正在迅速增加。此外，日本在再生醫學研究方面擁有強大的影響力，且原代細胞用於治療目的的使用正在增加。由於政府和私人組織大量投資支持的強大研發框架，歐洲正在經歷顯著成長。德國、法國、義大利、英國、西班牙和荷蘭等國家透過各自的生物製藥產業做出了巨大貢獻，塑造了歐洲、中東和非洲地區的整體進步格局。

FPNV定位矩陣

FPNV定位矩陣對於評估原代細胞市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對原電池市場供應商的現狀進行富有洞察力和深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動和突破性產品開發的智力見解。

本報告解決了以下關鍵問題：

1.原電池市場規模及預測是多少？

2.在原電池市場預測期內，我們應該考慮投資哪些產品和應用？

3.原代細胞市場的技術趨勢和法規結構是什麼？

4.原電池市場主要廠商的市場佔有率為何？

5.進入原代細胞市場的合適形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 藥物篩檢和細胞檢測的普及
      • 與現有方法相比，人類原代細胞的優勢
      • 單株抗體和個人化醫療日益受到關注
    • 抑制因素
      • 常見的細胞培養問題，例如污染
    • 機會
      • 生物技術和生物製藥產業的擴張
      • 使用原代細胞進行生物醫學研究的進展
    • 任務
      • 細胞生物學研究領域的倫理問題
  • 市場區隔分析
    • 起源：人們越來越傾向於使用原代人類細胞來準確地代表人類細胞反應
    • 細胞類型：在藥物開發和毒性測試中更多地使用皮膚細胞
    • 最終用戶：生命科學公司對原代細胞的使用激增，以確保實驗過程中獲得準確的結果
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章原代細胞市場：依來源分類

  • 介紹
  • 動物
  • 人類

第7章原代電池市場：依電池類型

  • 介紹
  • 皮膚細胞
  • 胃腸細胞
  • 心臟細胞
  • 造血細胞
  • 肝細胞
  • 肺細胞
  • 肌肉骨骼細胞
  • 腎臟細胞

第 8 章 原電池市場：依最終用戶分類

  • 介紹
  • 生命科學公司
  • 研究機構

第9章美洲原代細胞市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太原電池市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲原電池市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4F4C36263622

[195 Pages Report] The Primary Cells Market size was estimated at USD 1.43 billion in 2023 and expected to reach USD 1.60 billion in 2024, at a CAGR 12.10% to reach USD 3.18 billion by 2030.

Primary cells are the fundamental building blocks of tissues and organs and exhibit natural biological behavior similar to their origin, making them an essential tool in various scientific applications. Increased investment in regenerative medicine and cell-based research drives primary cells' need to develop innovative therapeutic solutions. Technological advancements such as CRISPR gene-editing techniques have expanded primary cell usage by offering more precise manipulation tools for targeted therapies. However, primary cells may exhibit donor-to-donor variability due to genetic and environmental factors influencing their biology, potentially limiting their reproducibility in research settings. Nevertheless, the increasing number of life sciences collaborations between academic institutions, research laboratories, and biopharmaceutical manufacturers is expected to contribute to exploring primary cell-based therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.60 billion
Forecast Year [2030] USD 3.18 billion
CAGR (%) 12.10%

Origin: Increasing preference for human primary cells for accurate representations of human cellular responses

Animal primary cells are isolated directly from animal tissues and retain many of their original physiological properties, making them a valuable tool for in vitro studies and preclinical research. Researchers commonly use animal primary cells to study biological processes, screen drugs, and develop new disease therapies. The advantages of using animal primary cells include ease of availability, low cost compared to human primary cells, and the ability to model species-specific responses to treatments. Human primary cells are derived directly from human tissues and maintain many characteristics similar to their origin tissue. They are essential for understanding human biology, drug discovery, pathology, toxicity testing, and regenerative medicine applications. Human primary cell cultures provide more accurate representations of human cellular responses than immortalized cell lines or animal models. Human primary cells are often preferred for applications requiring a higher biological relevance, especially when studying human-specific diseases or developing patient therapies.

Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing

Dermatocytes are essential for researchers studying skin biology, wound healing, and dermatological disorders. They are widely used in drug development and toxicity testing. Gastrointestinal cells encompass a variety of cell types found in the gastrointestinal tract and are vital for research on gut health, nutrient absorption, and digestive disorders. Cardiomyocytes or heart cells are central to cardiovascular research involving cardiac development, function, and disease modeling. Hematopoietic stem cells (HSCs) give rise to all blood cell types and have diverse applications in regenerative medicine & transplantation therapies for hematological disorders such as leukemia or lymphoma. Primary hepatocytes are crucial to research involving liver function, metabolism, and toxicity testing of pharmaceuticals. Pulmonary research relies heavily on primary lung cells for studying respiratory diseases such as asthma, COPD, or lung cancer. Musculoskeletal cells consist of bone, cartilage, and muscle-forming cells and are imperative in musculoskeletal disorder studies, regenerative medicine applications & tissue engineering solutions. Kidney or renal primary cells offer insightful models for nephrology research, including kidney disease progression & drug toxicity assessment on renal functions.

End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation

Life science companies, including biotechnology, pharmaceutical, and medical device industries, heavily invest in research and development activities. These companies require primary cells for drug discovery, toxicity testing, cell therapy development, regenerative medicine applications, and manufacturing biological products. These companies involve high-quality primary cells with well-characterized phenotypes to ensure accurate results during experimentation. Research institutes encompass academic institutions and government-funded laboratories focused on understanding fundamental biological processes and disease mechanisms. Primary cells are essential to their research efforts due to their relevance as model systems in studying cellular processes or responses under various experimental conditions. The preference of research institutes revolves around the availability of diverse primary cell types, sourced ethically and with proper documentation, to ensure reproducibility across different laboratories.

Regional Insights

Americas region showcases significant growth primarily due to the presence of well-established biotechnology and pharmaceutical industries in countries such as the United States and Canada. The rapid adoption of advanced technologies in cell culture methodologies and increasing investments in research & development activities contribute to this region's strong performance. Furthermore, several government initiatives aimed at promoting novel therapies using primary cells have spurred growth in this sector. In the APAC region, countries such as China and India are experiencing considerable expansion of their biopharmaceutical sectors. This is attributed to factors such as a growing elderly population with a higher prevalence of chronic diseases requiring innovative treatment options, increased healthcare expenditure, and a greater focus on research & development activities. As a result, there has been a surge in demand for primary cells within this region. Additionally, Japan boasts a strong presence in regenerative medicine research, which has led to increased utilization of primary cells for therapeutic purposes. Europe is experiencing significant growth with its robust R&D framework supported by substantial investments from both governmental organizations and private entities. Countries such as Germany, France, Italy, UK, Spain, and the Netherlands have all contributed significantly through their respective biotechnology pharmaceutical industries, shaping up an overall progressive scenario within the EMEA region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Primary Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Primary Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Primary Cells Market, highlighting leading vendors and their innovative profiles. These include Biopredic International, Corning Incorporated, Danaher Corporation, FUJIFILM Irvine Scientific, Inc., Lonza AG, PromoCell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, The Bio Convergence Company, The Merck Group, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Primary Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Origin
    • Animal Primary Cells
    • Human Primary Cells
  • Cell Type
    • Dermatocytes
    • Gastrointestinal Cells
    • Heart Cells
    • Hematopoietic Cells
    • Hepatocytes
      • Cryopreserved Hepatocytes
      • Fresh Hepatocytes
    • Lung Cells
    • Musculoskeletal Cells
    • Renal Cells
  • End-User
    • Life Science Companies
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Primary Cells Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Primary Cells Market?

3. What are the technology trends and regulatory frameworks in the Primary Cells Market?

4. What is the market share of the leading vendors in the Primary Cells Market?

5. Which modes and strategic moves are suitable for entering the Primary Cells Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing acceptance in drug screening and cell based assays
      • 5.1.1.2. Advantages of primary human cells over other existing methods
      • 5.1.1.3. Growing focus on monoclonal antibodies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Common cell culture problems such as contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding biotechnology and biopharmaceutical industries
      • 5.1.3.2. Advancements in biomedical research using primary cells
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues in cell biology research field
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Origin: Increasing preference for human primary cells for accurate representations of human cellular responses
    • 5.2.2. Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing
    • 5.2.3. End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Primary Cells Market, by Origin

  • 6.1. Introduction
  • 6.2. Animal Primary Cells
  • 6.3. Human Primary Cells

7. Primary Cells Market, by Cell Type

  • 7.1. Introduction
  • 7.2. Dermatocytes
  • 7.3. Gastrointestinal Cells
  • 7.4. Heart Cells
  • 7.5. Hematopoietic Cells
  • 7.6. Hepatocytes
  • 7.7. Lung Cells
  • 7.8. Musculoskeletal Cells
  • 7.9. Renal Cells

8. Primary Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Life Science Companies
  • 8.3. Research Institutes

9. Americas Primary Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Primary Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Primary Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Primary Human Cells for Microphysiological Systems
    • 12.3.2. AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
    • 12.3.3. Human Cell Design Launches Endoc-BH5, an Advanced Human Beta Cell Model enabling New Discoveries in Type 1 and 2 Diabetes Research
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PRIMARY CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. PRIMARY CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PRIMARY CELLS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRIMARY CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PRIMARY CELLS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 359. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 360. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 361. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 362. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 369. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 370. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 372. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 373. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 374. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 375. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 376. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 377. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 378. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 379. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 380. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023